Analysts are bullish on several biotech companies, including GH Research, Cybin D/B/A Helus Pharma, and COMPASS Pathways, following a psychedelics symposium and positive model updates, with Baird lowering Bright Minds Biosciences' price target but maintaining an Outperform rating.

This article highlights the biggest stock movers on Tuesday, including ZIM and CMPS, indicating significant market activity for these companies.